DNLI

$20.967.76%1.51

After Hours: 20.960.00 0.00%

Denali Therapeutics Inc (DNLI)

Date: O: H: L: C: Vol:

Denali Therapeutics Inc stock is traded at $20.96, with a volume of 4,654,721. It is up +7.76% in the last 24 hours and up +4.80% over the past month. Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.

Previous Close:

$19.45

Open:

$21.23

24h Volume:

4,654,721

Relative Volume:

2.79

Market Cap:

$3.35B

Revenue:

$1.27M

Net Income/Loss:

-$508.02M

P/E Ratio:

EPS:

-$2.88

Net Cash Flow:

-$419.23M

1W Performance:

+8.66%

1M Performance:

+4.80%

6M Performance:

+12.27%

1Y Performance:

+40.48%

1-Day Range:

$19.75$22.19

1-Week Range:

$18.32$22.19

52-Week Range:

$13.75$27.30

Denali Therapeutics Inc Stock (DNLI) Company Profile

Name

Denali Therapeutics Inc

Sector

Healthcare

Industry

Biotechnology

Phone

(650) 866-8547

Address

161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, USA

Employee

503

Next Earnings Date

null

Latest SEC Filings

SEC

DNLI's Discussions on X

Market Cap

Revenue

Net Income

Cash Flow

EPS

Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-13-26	Resumed	JP Morgan	Overweight
Mar-26-26	Reiterated	H.C. Wainwright	Buy
Feb-24-26	Initiated	Wolfe Research	Peer Perform
Jan-07-26	Resumed	UBS	Buy
Apr-10-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Mar-07-25	Resumed	Morgan Stanley	Overweight
Feb-11-25	Initiated	Deutsche Bank	Buy
Jan-07-25	Initiated	Robert W. Baird	Outperform
Jan-03-25	Initiated	William Blair	Outperform
Dec-16-24	Upgrade	Stifel	Hold → Buy
Oct-10-24	Resumed	Raymond James	Mkt Perform
Oct-07-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Dec-13-23	Initiated	Citigroup	Buy
Nov-20-23	Resumed	JP Morgan	Overweight
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight
Sep-06-23	Initiated	B. Riley Securities	Buy
Jan-30-23	Initiated	SVB Securities	Outperform
Dec-05-22	Initiated	Cowen	Outperform
Nov-02-22	Upgrade	BTIG Research	Neutral → Buy
Nov-02-22	Initiated	BofA Securities	Buy
Jun-23-22	Initiated	Berenberg	Buy
Dec-10-21	Resumed	Raymond James	Mkt Perform
Sep-21-21	Initiated	Oppenheimer	Outperform
Sep-01-21	Initiated	SMBC Nikko	Outperform
May-18-21	Initiated	UBS	Buy
Feb-26-21	Reiterated	H.C. Wainwright	Buy
Feb-10-21	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-11-20	Reiterated	H.C. Wainwright	Buy
Oct-16-20	Downgrade	BTIG Research	Buy → Neutral
Sep-14-20	Resumed	JP Morgan	Overweight
Aug-20-20	Reiterated	H.C. Wainwright	Buy
Mar-13-20	Upgrade	Evercore ISI	In-line → Outperform
Feb-28-20	Upgrade	Wedbush	Neutral → Outperform
Feb-24-20	Initiated	Jefferies	Buy
Feb-19-20	Initiated	Stifel	Hold
Jan-27-20	Upgrade	Goldman	Neutral → Buy
Sep-26-19	Initiated	Wedbush	Neutral
Sep-13-19	Initiated	Nomura	Buy
Aug-09-19	Initiated	BTIG Research	Buy
Jun-26-19	Initiated	H.C. Wainwright	Buy
Nov-15-18	Initiated	Cantor Fitzgerald	Overweight
Nov-12-18	Initiated	Janney	Buy
Mar-12-18	Downgrade	Evercore ISI	Outperform → In-line
Jan-02-18	Initiated	Evercore ISI	Outperform
Jan-02-18	Initiated	Goldman	Neutral
Jan-02-18	Initiated	JP Morgan	Overweight
Jan-02-18	Initiated	Morgan Stanley	Overweight

Denali Therapeutics Inc Stock (DNLI) Financials Data

Period	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period End Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	0.00	0.00	330.53	108.46	48.66
Research and development USD (M)	418.78	396.44	423.88	358.73	265.35
Operating expenses USD (M)	555.34	501.88	527.23	449.21	344.41
Operating income USD (M)	-555.34	-487.34	-196.70	-340.74	-295.75
Income before tax USD (M)	-	-	330.53	108.46	48.66
Income tax expense USD (M)	0.10	0.07	0.03	0.02	-0.58
Net income USD (M)	-512.54	-422.77	-145.22	-325.99	-290.58
Basic EPS USD/shares	-2.97	-2.57	-1.06	-2.60	-2.39
Diluted EPS USD/shares	-2.97	-2.57	-1.06	-2.60	-2.39
Basic weighted shares shares (M)	172.65	164.47	137.37	125.53	121.52
Diluted weighted shares shares (M)	172.65	164.47	137.37	125.53	121.52

Denali Therapeutics Inc Stock (DNLI) Insider Trading

Chin Peter ScottSep 04 '26
Officer
Transaction
Proposed Sale
Cost
$22.29
#Shares
1,654
Value ($)
36,867
#Shares Total
0
Chin Peter ScottSep 04 '26
Chief Medical Officer
Transaction
Sale
Cost
$22.29
#Shares
1,654
Value ($)
36,868
#Shares Total
204,538
NANCY THORNBERRYSep 02 '26
Director
Transaction
Proposed Sale
Cost
$23.27
#Shares
11,439
Value ($)
266,128
#Shares Total
0
Thornberry NancySep 02 '26
Director
Transaction
Sale
Cost
$22.90
#Shares
11,439
Value ($)
261,929
#Shares Total
19,686
Schuth Alexander O.Sep 01 '26
COFO and Secretary
Transaction
Sale
Cost
$23.44
#Shares
2,768
Value ($)
64,882
#Shares Total
278,995
ALEXANDER SCHUTHSep 01 '26
Officer
Transaction
Proposed Sale
Cost
$23.76
#Shares
2,768
Value ($)
65,768
#Shares Total
0
Schuth Alexander O.Aug 11 '26
COFO and Secretary
Transaction
Sale
Cost
$25.07
#Shares
2,857
Value ($)
71,625
#Shares Total
281,763
Schuth Alexander O.Aug 11 '26
Officer
Transaction
Proposed Sale
Cost
$25.07
#Shares
2,857
Value ($)
71,624
#Shares Total
0
CAROLE HOFeb 05 '26
Former Affiliate
Transaction
Proposed Sale
Cost
$20.29
#Shares
39,490
Value ($)
801,394
#Shares Total
0
CAROLE HOFeb 04 '26
Former Affiliate
Transaction
Proposed Sale
Cost
$21.18
#Shares
150,000
Value ($)
3,176,970
#Shares Total
0

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Chin Peter Scott	Officer	Sep 04 '26	Proposed Sale	$22.29	1,654	36,867	0
Chin Peter Scott	Chief Medical Officer	Sep 04 '26	Sale	$22.29	1,654	36,868	204,538
NANCY THORNBERRY	Director	Sep 02 '26	Proposed Sale	$23.27	11,439	266,128	0
Thornberry Nancy	Director	Sep 02 '26	Sale	$22.90	11,439	261,929	19,686
Schuth Alexander O.	COFO and Secretary	Sep 01 '26	Sale	$23.44	2,768	64,882	278,995
ALEXANDER SCHUTH	Officer	Sep 01 '26	Proposed Sale	$23.76	2,768	65,768	0
Schuth Alexander O.	COFO and Secretary	Aug 11 '26	Sale	$25.07	2,857	71,625	281,763
Schuth Alexander O.	Officer	Aug 11 '26	Proposed Sale	$25.07	2,857	71,624	0
CAROLE HO	Former Affiliate	Feb 05 '26	Proposed Sale	$20.29	39,490	801,394	0
CAROLE HO	Former Affiliate	Feb 04 '26	Proposed Sale	$21.18	150,000	3,176,970	0

Denali Therapeutics Inc Stock (DNLI) Latest News

Nov 03, 2026